Abstract
Recent studies revealed an exceedingly high mortality with diastolic heart failure that was previously regarded as relatively benign compared to systolic heart failure. Prominent risk factors for diastolic heart failure are increasing age, hypertension and diabetes. These risk factors are associated with coronary microvascular rarefaction and resultant decreased coronary flow reserve, thereby rendering the myocardium vulnerable to ischemia. We discuss the importance of angiogenic gene programming in preserving the coronary microvasculature, preserving cardiac function and altering disease course. Further, we discuss the possible utility of therapies that activate hypoxia inducible factor-1 in preventing rarefaction of the coronary microvasculature and maintaining cardiac diastolic function.
Keywords: Endothelial progenitor cell, angiogenesis, neovascularization, hypoxia inducible factor, heart failure, hypertension, diabetes, microvasculature
Current Vascular Pharmacology
Title: The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Volume: 6 Issue: 4
Author(s): Michel R. Hoenig, Cesario Bianchi, Anthony Rosenzweig and Frank W. Sellke
Affiliation:
Keywords: Endothelial progenitor cell, angiogenesis, neovascularization, hypoxia inducible factor, heart failure, hypertension, diabetes, microvasculature
Abstract: Recent studies revealed an exceedingly high mortality with diastolic heart failure that was previously regarded as relatively benign compared to systolic heart failure. Prominent risk factors for diastolic heart failure are increasing age, hypertension and diabetes. These risk factors are associated with coronary microvascular rarefaction and resultant decreased coronary flow reserve, thereby rendering the myocardium vulnerable to ischemia. We discuss the importance of angiogenic gene programming in preserving the coronary microvasculature, preserving cardiac function and altering disease course. Further, we discuss the possible utility of therapies that activate hypoxia inducible factor-1 in preventing rarefaction of the coronary microvasculature and maintaining cardiac diastolic function.
Export Options
About this article
Cite this article as:
Hoenig R. Michel, Bianchi Cesario, Rosenzweig Anthony and Sellke W. Frank, The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure, Current Vascular Pharmacology 2008; 6 (4) . https://dx.doi.org/10.2174/157016108785909779
DOI https://dx.doi.org/10.2174/157016108785909779 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
High-dose Cholecalciferol Supplementation Reducing Morning Blood Pressure in Normotensive DM1 Patients
Current Diabetes Reviews Renin Inhibition as a New Strategy to Combat Cardiovascular Disease
Current Hypertension Reviews Molecular Mechanism of Aggravation of Hypertensive Organ Damages by Short-Term Blood Pressure Variability
Current Hypertension Reviews Patent Selections
Recent Patents on Cardiovascular Drug Discovery Novel Classes of Dimer Antitumour Drug Candidates
Current Pharmaceutical Design Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma
Current Vascular Pharmacology Anti-Arrhythmic Properties of N-3 Poly-Unsaturated Fatty Acids (n-3 PUFA)
Current Medicinal Chemistry Transmembrane Phosphatases and Cancer Development, the Role of Protein Tyrosine Phosphatase-kappa (PTPκ) and Protein Tyrosine Phosphatase-mu (PTPμ)
Current Signal Transduction Therapy Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Isolation and Proteomic Characterization of Bacterial Extracellular Membrane Vesicles
Current Protein & Peptide Science The Risk of Adverse Drug Reactions in Older Patients: Beyond Drug Metabolism
Current Drug Metabolism Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy
Current Topics in Medicinal Chemistry Endothelin and the Ischaemic Heart
Current Vascular Pharmacology Stem Cell Aging and Age-Related Cardiovascular Disease: Perspectives of Treatment by Ex-vivo Stem Cell Rejuvenation
Current Drug Targets The Origins of Aging: Evidence that Aging is an Adaptive Phenotype
Current Aging Science Genesis of Dihydropyrimidinone Calcium Channel Blockers: Recent Progress in Structure-Activity Relationships and Other Effects
Mini-Reviews in Medicinal Chemistry TNFα as Therapeutic Target: New Drugs, More Applications
Current Drug Targets - Inflammation & Allergy